Last reviewed · How we verify
NCT07519811: oncOPAL
LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)
NA trial testing LLM-Generated Plain-Language Patient Synopsis in Hematologic Neoplasms in 150 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Technical University of Munich |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 150 |
| Start date | 1 April 2026 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- LLM-Generated Plain-Language Patient Synopsis
Conditions studied
- Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
- Oncologic Disorders — all drugs for Oncologic Disorders →
Sponsor
Technical University of Munich
Who can join
18 and older, any sex, with Hematologic Neoplasms or Oncologic Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system. When patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it. Patients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version. After reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07519811
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Neoplasms
Currently open trials in the same condition.
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
- NCT06685848 — Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion · NA · recruiting
- NCT06433349 — A Multi-center Investigation of Family Health. · recruiting
- NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
Other Technical University of Munich trials
Trials by the same sponsor.
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
- NCT07077005 — Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
- NCT07212699 — Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App · NA · recruiting
- NCT06823271 — Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy · NA · completed
- NCT07183475 — Return to Sports After Knee Arthroplasty · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07519811 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Technical University of Munich
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07519811.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing